FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2233142754> ?p ?o ?g. }

• W2233142754 endingPage "160" @default.
• W2233142754 startingPage "153" @default.
• W2233142754 abstract "Objective To analyse the proportion of men taking tadalafil 5 mg once daily who experience a combined improvement in symptoms of both erectile dysfunction ( ED ) and lower urinary tract symptoms associated with benign prostatic hyperplasia ( LUTS / BPH ). Materials and Methods The data from men aged ≥45 years randomized to tadalafil 5 mg once daily or placebo enrolled in one of four randomized, placebo‐controlled LUTS / BPH clinical trials were analysed ( N = 927). A novel classification of ‘combined responders’ to ED and LUTS / BPH treatment was defined, based on published criteria for men who showed improvement in both International Index of Erectile Function – Erectile Function domain ( IIEF ‐ EF ) score and total International Prostate Symptom Score ( IPSS ). Descriptive analyses assessed the covariate distribution by responder status. Unadjusted and adjusted logistic regressions provided odds ratios with 95% confidence intervals comparing combined responders with all others (partial and non‐responders). Results Among men randomized to tadalafil 5 mg, 40.5% were combined responders ( n = 189). Among placebo randomized men, 18.3% were combined responders ( n = 84). Combined responders, in the total population, had the highest baseline IPSS and lowest baseline IIEF ‐ EF scores, corresponding to the highest level of dysfunction. The majority of men were aged ≤65 years, white, non‐obese, non‐smokers, and regular alcohol consumers. Only treatment, baseline IPSS , baseline IIEF ‐ EF , obesity and psychoactive medication use were significantly associated with responder status ( P ≤ 0.05). Tadalafil‐treated men had 2.8 times significantly increased adjusted odds of being combined responders vs non‐responders ( P < 0.001). For each unit decrease in baseline IIEF ‐ EF or alcoholic drink consumption per week there was a 4% significant increase in the adjusted odds of being a combined responder to tadalafil therapy. Conclusions This novel measure of combined response is useful in differentiating patients with clinically relevant symptom improvement for both ED and LUTS / BPH after treatment with tadalafil 5 mg once daily vs placebo. This combined responder measure may be useful in future assessment of treatment benefits across patient groups after various types of treatment intervention (e.g. surgical vs pharmacotherapy vs non‐pharmacological intervention)." @default.
• W2233142754 created "2016-06-24" @default.
• W2233142754 creator A5013180579 @default.
• W2233142754 creator A5019825677 @default.
• W2233142754 creator A5031881982 @default.
• W2233142754 creator A5049019006 @default.
• W2233142754 creator A5059154237 @default.
• W2233142754 creator A5062433452 @default.
• W2233142754 date "2016-02-11" @default.
• W2233142754 modified "2023-10-04" @default.
• W2233142754 title "Erectile dysfunction and lower urinary tract symptoms associated with benign prostatic hyperplasia (LUTS/BPH) combined responders to tadalafil after 12 weeks of treatment" @default.
• W2233142754 cites W1515157556 @default.
• W2233142754 cites W1518162929 @default.
• W2233142754 cites W1538235949 @default.
• W2233142754 cites W1947843794 @default.
• W2233142754 cites W1965679809 @default.
• W2233142754 cites W198934061 @default.
• W2233142754 cites W1995256786 @default.
• W2233142754 cites W2000000918 @default.
• W2233142754 cites W2006615433 @default.
• W2233142754 cites W2013459993 @default.
• W2233142754 cites W2016054225 @default.
• W2233142754 cites W2018377518 @default.
• W2233142754 cites W2029221012 @default.
• W2233142754 cites W2034349815 @default.
• W2233142754 cites W2036237726 @default.
• W2233142754 cites W2050093658 @default.
• W2233142754 cites W2073978463 @default.
• W2233142754 cites W2087378939 @default.
• W2233142754 cites W2132697170 @default.
• W2233142754 cites W2135421268 @default.
• W2233142754 cites W2154659002 @default.
• W2233142754 cites W2159157945 @default.
• W2233142754 cites W2159379731 @default.
• W2233142754 cites W2395601383 @default.
• W2233142754 cites W4319720823 @default.
• W2233142754 doi "https://doi.org/10.1111/bju.13406" @default.
• W2233142754 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/26765325" @default.
• W2233142754 hasPublicationYear "2016" @default.
• W2233142754 type Work @default.
• W2233142754 sameAs 2233142754 @default.
• W2233142754 citedByCount "11" @default.
• W2233142754 countsByYear W22331427542017 @default.
• W2233142754 countsByYear W22331427542019 @default.
• W2233142754 countsByYear W22331427542020 @default.
• W2233142754 countsByYear W22331427542021 @default.
• W2233142754 countsByYear W22331427542022 @default.
• W2233142754 crossrefType "journal-article" @default.
• W2233142754 hasAuthorship W2233142754A5013180579 @default.
• W2233142754 hasAuthorship W2233142754A5019825677 @default.
• W2233142754 hasAuthorship W2233142754A5031881982 @default.
• W2233142754 hasAuthorship W2233142754A5049019006 @default.
• W2233142754 hasAuthorship W2233142754A5059154237 @default.
• W2233142754 hasAuthorship W2233142754A5062433452 @default.
• W2233142754 hasBestOaLocation W22331427541 @default.
• W2233142754 hasConcept C121608353 @default.
• W2233142754 hasConcept C126322002 @default.
• W2233142754 hasConcept C126894567 @default.
• W2233142754 hasConcept C142724271 @default.
• W2233142754 hasConcept C156957248 @default.
• W2233142754 hasConcept C168563851 @default.
• W2233142754 hasConcept C204787440 @default.
• W2233142754 hasConcept C27081682 @default.
• W2233142754 hasConcept C2776235491 @default.
• W2233142754 hasConcept C2776547966 @default.
• W2233142754 hasConcept C2779478474 @default.
• W2233142754 hasConcept C2779929075 @default.
• W2233142754 hasConcept C2780816001 @default.
• W2233142754 hasConcept C2908647359 @default.
• W2233142754 hasConcept C29456083 @default.
• W2233142754 hasConcept C71924100 @default.
• W2233142754 hasConcept C99454951 @default.
• W2233142754 hasConceptScore W2233142754C121608353 @default.
• W2233142754 hasConceptScore W2233142754C126322002 @default.
• W2233142754 hasConceptScore W2233142754C126894567 @default.
• W2233142754 hasConceptScore W2233142754C142724271 @default.
• W2233142754 hasConceptScore W2233142754C156957248 @default.
• W2233142754 hasConceptScore W2233142754C168563851 @default.
• W2233142754 hasConceptScore W2233142754C204787440 @default.
• W2233142754 hasConceptScore W2233142754C27081682 @default.
• W2233142754 hasConceptScore W2233142754C2776235491 @default.
• W2233142754 hasConceptScore W2233142754C2776547966 @default.
• W2233142754 hasConceptScore W2233142754C2779478474 @default.
• W2233142754 hasConceptScore W2233142754C2779929075 @default.
• W2233142754 hasConceptScore W2233142754C2780816001 @default.
• W2233142754 hasConceptScore W2233142754C2908647359 @default.
• W2233142754 hasConceptScore W2233142754C29456083 @default.
• W2233142754 hasConceptScore W2233142754C71924100 @default.
• W2233142754 hasConceptScore W2233142754C99454951 @default.
• W2233142754 hasIssue "1" @default.
• W2233142754 hasLocation W22331427541 @default.
• W2233142754 hasLocation W22331427542 @default.
• W2233142754 hasOpenAccess W2233142754 @default.
• W2233142754 hasPrimaryLocation W22331427541 @default.
• W2233142754 hasRelatedWork W2037716159 @default.
• W2233142754 hasRelatedWork W2051497077 @default.
• W2233142754 hasRelatedWork W2070170982 @default.
• W2233142754 hasRelatedWork W2074093603 @default.

• next